Cargando…

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis

New meta‐analyses are presented that provide further evidence supporting the effectiveness of oral prolonged‐release mesalazine compared to other oral mesalazines as induction therapy in patients with moderately active ulcerative colitis.[Image: see text]

Detalles Bibliográficos
Autores principales:	Paridaens, Kristine, Fullarton, John R, Travis, Simon P L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366489/ https://www.ncbi.nlm.nih.gov/pubmed/37496812 http://dx.doi.org/10.1002/jgh3.12935

Ejemplares similares

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2016)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Mesalazine-Induced Interstitial Nephritis in a Patient With Ulcerative Colitis
por: da Cunha Marques, José, et al.
Publicado: (2022)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration
por: Kawashima, Kousaku, et al.
Publicado: (2014)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials
por: Zheng, Xin, et al.
Publicado: (2019)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
por: Takeshima, Fuminao, et al.
Publicado: (2014)

Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
por: Tsuboi, Rumiko, et al.
Publicado: (2018)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2022)

Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study
por: Matsumoto, Satohiro, et al.
Publicado: (2015)

pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review)
por: Deissler, Helmut, et al.
Publicado: (2021)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
por: Arai, Yoshinori, et al.
Publicado: (2011)

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report
por: Huang, Po-Han, et al.
Publicado: (2018)

Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis
por: Pan, Chengyu, et al.
Publicado: (2022)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
por: Khanna, Raoul Kanav, et al.
Publicado: (2018)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2021)

Ulcerative Colitis Activity Presenting as Fever of Unknown Origin, in a Patient with Longstanding Disease under Continuous Treatment with Mesalazine
por: Voukelatou, Panagiota, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_50v5qniipqqprnkck08jp1g3rl